<DOC>
	<DOCNO>NCT00752635</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety norgestimate-ethinyl estradiol compart cyproterone acetate-ethinyl estradiol among female patient moderate acne vulgaris .</brief_summary>
	<brief_title>Comparison Efficacy Safety Norgestimate-ethinyl Estradiol Cyproterone Acetate-ethinyl Estradiol Treatment Acne Vulgaris</brief_title>
	<detailed_description>This study evaluate efficacy safety TriCilest compart Diane-35 among female patient moderate acne vulgaris . The study design double-blind , randomize , parallel active control . The sponsor plan recruit approximately 50 patient complete 40 evaluable patient . At end study , total 48 patient randomize . TriCilest ( noregestimate-ethinyl estradiol ) , 0.18mg-0.035mg 0.215mg-0.035mg 0.25mg-0.035mg , Oral admistration , The duration three consecutive menstrual cycle .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Female adult suffer moderate acne vulgaris ( grade II III ) With 6 100 comedo ( noninflammatory lesion ) With 10 50 inflammatory lesion ( papule pustule ) With few 5 nodule Agree condom diaphragm , spermicide medically approve effective barrier method contraceptive nonhormonal IUD Agree take treatment acne supply study drug three month treatment phase Documented inform consent participate trial day enter study Patients , investigator 's opinion , understand follow instruction give study Who pregnant nursing Who clinical depression suicidal require immediate treatment depression Who know hypersensitivity ingredient Who currently significant adverse experience ethinyl estradiol norgestimate Who coexist medical condition take concomitant medication likely interfere safe administration TriCilest and/or Diane35 , investigator 's opinion Who take systemic retinoids , systemic antimicrobial , topical acne treatment within 6 month , 1 month , 2 week prior enrollment , respectively Who follow contraindication oral contraceptive : Current thrombophlebitis thromboembolic disorder , past history deep vein thrombophlebitis thromboembolic disorder , cerebral vascular coronary artery disease know severe hypertension , diabetes vascular involvement , know suspect carcinoma breast , know suspected estrogendependent neoplasia , undiagnosed , abnormal genital bleeding , benign malignant liver tumor , jaundice severe liver disease , neurovascular lesion eye serious visual disturbance , know allergic reaction sensitivity TriCilest Diane 35 Who take investigational medication within 30 day prior enter study ( within period five time halflife halflife metabolite )</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TriCilest</keyword>
	<keyword>acne vulgaris</keyword>
</DOC>